The Kindest Cut

In the first of two papers for the Macdonald-Laurier institute examining the history and impact of drug price controls in Canada, I argue for doing away with the Patented Medicine Prices Review Board and leading nations toward a more equitable sharing of the costs of pharmaceutical development. The first paper is here, and the second will be published shortly.